Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

The rapid increase of rapid microbial testing - Market to reach $19.5 billion by 2022

SMi Group
Posted on: 06 Sep 17
The rapid increase of rapid microbial testing - Market to reach $19.5 billion by 2022

Rapid microbiological tests are gaining momentum in the global market as a reliable and cost-effective method to track and monitor all types of microorganisms in clinical as well as industrial settings. In addition, rapid microbiology detection enables faster and more accurate methods to assist in the rapid diagnosis and treatment of patients or to provide safe and reliable food, water, and pharmaceuticals. 

The pharmaceutical microbiology market is wide open and receptive to advancing rapid diagnostic technologies to improve patient management, exponential population growth and aging conventional technology will only intensify the pace of development. In light of this development, SMi's pharmaceutical Microbiology East Coast conference will shed insight onto the current designed therapies and rapid microbial detection trends.

SMi is pleased to have Founder & CEO of ImmuneBiotech AB, Shahram Lavasani presenting one of this year's Rapid Microbial spotlight sessions. Shahram's talk will focus on how the gut microbiome plays an essential role in disease regulation and efficacy of therapies, whilst assessing how altered microbial communities, also termed dysbiosis, have been observed in many intestinal and extra-intestinal inflammatory disorders. There is not yet a clear understanding whether dysbiosis is a cause or a consequence of the diseases. Microbial therapies which only target the dysbiosis have shown limited success. 

The importance of multiple-target drug cocktails comprising commensal bacteria will also be a topic of discussion, along with an evaluation of how the bacterial library, screening technologies and design of potential and affordable drugs will be presented with particular focus on successful products that treat Irritable Bowel Syndrome (IBS) and Clostridium Difficile Infection.

For more on information on this year's selection of hot topics, visit the Pharmaceutical Microbiology East Coast website at

This year’s conference will gather a global audience of scientific leaders, funding bodies and drug development experts, providing a focal point to discuss funding opportunities and clinical advancements in microbial control strategies and quality methods.

The notable speaker line-up at Pharmaceutical Microbiology East Coast will also include Microbiology Consulting, LLC, Genentech, GlaxoSmithKline, Johnson & Johnson, Eli Lily, Sanofi Pasteur and many more!


For those wanting to attend, there is currently a manager’s special offer available; book by September 15th, 2017 to save $800 off the conference price. Register at   

Pharmaceutical Microbiology East Coast 2017 is sponsored by Associates of Cape Cod, Inc. BioMérieux and Charles River.

For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail

For delegate enquiries: Contact Sean Vaghela on +44 (0) 20 7827 6744 or email

For media enquiries, contact Kyra Williams on +44 (0) 20 7827 6012 or email  


Pharmaceutical Microbiology East Coast

November 13 – 14, 2017

Iselin, New Jersey, USA
Contact e-mail:
Contact tel: +44 (0) 207 827 6012

For more information:

Editor's Details

Kyra Williams
SMi Group

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.